ファージが多剤耐性菌に対抗する仕組みを解明 Study shows how phages fight multidrug-resistant pathogens
2022-07-20 テキサス A&M大学
研究者は、この治療法およびファージ療法の他の可能性についての研究を完了しました。
彼らの研究は、科学雑誌「Nature Communications」に最近掲載されました。
抗菌薬耐性の脅威は世界的な問題となっており、世界保健機関は、2050年までに世界で少なくとも年間5000万人が抗菌薬耐性で死亡する可能性があると推定しています。ファージ・テクノロジー・センターの科学者たちは、ファージ治療薬がこうした耐性菌感染症に対抗するために使用できると考えています。
<関連情報>
- https://agrilifetoday.tamu.edu/2022/07/20/managing-phage-therapy-to-help-save-lives/
- https://www.nature.com/articles/s41467-022-31455-5
Comparative genomics of Acinetobacter baumannii and therapeutic bacteriophages from a patient undergoing phage therapy
Mei Liu,Adriana Hernandez-Morales,James Clark,Tram Le,Biswajit Biswas,Kimberly A. Bishop-Lilly,Matthew Henry,Javier Quinones,Logan J. Voegtly,Regina Z. Cer,Theron Hamilton,Robert T. Schooley,Scott Salka,Ry Young & Jason J. Gill
Nature Communications
Abstract
In 2016, a 68-year-old patient with a disseminated multidrug-resistant Acinetobacter baumannii infection was successfully treated using lytic bacteriophages. Here we report the genomes of the nine phages used for treatment and three strains of A. baumannii isolated prior to and during treatment. The phages used in the initial treatment are related, T4-like myophages. Analysis of 19 A. baumannii isolates collected before and during phage treatment shows that resistance to the T4-like phages appeared two days following the start of treatment. We generate complete genomic sequences for three A. baumannii strains (TP1, TP2 and TP3) collected before and during treatment, supporting a clonal relationship. Furthermore, we use strain TP1 to select for increased resistance to five of the phages in vitro, and identify mutations that are also found in phage-insensitive isolates TP2 and TP3 (which evolved in vivo during phage treatment). These results support that in vitro investigations can produce results that are relevant to the in vivo environment.
